Announcements

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers

1.Date of the board of directors resolution:2024/03/11 2.Name and title of the managerial officer with permission to engage in competitive conduct: Heidi Wang/ CEO Ming-Tain Lai/ Chief Scientific Officer Colin …

Announcement of 2023 Consolidated Financial Statements were approved by the Board of Directors

1.Date of the board of directors submitted or approved:2024/03/11 2.Date of the audit committee approved:2024/03/08 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): …

The Company’s Board of Directors resolved to convene the 2024 Annual General Shareholders’ Meeting

1.Date of the board of directors resolution:2024/03/11 2.General shareholders’ meeting date:2024/06/17 3.General shareholders’ meeting location: Masterlink Securities Education and Training Center (11F., No.97, Sec. 2, Dunhua S. Rd., Taipei City) …

Announcement of not Distributing Dividends in 2023

1.Date of the board of directors resolution:2024/03/11 2.Year or quarter which dividends belong to :2023 3.Period which dividends belong to:2023/1/1 to 2023/12/31 4.Appropriations of earnings in cash dividends to shareholders …

OBI announces the termination of OBI-3424-001 trial while continuing the collaboration of OBI-3424 with partners

1.Date of occurrence of the event:2024/03/11 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: Following …

Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA

1.Date of occurrence of the event:2024/02/29 2.New drug name or code:OBI-858 Novel Botulinum Neurotoxin 3.Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic …

Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

1.Date of occurrence of the event:2024/01/31 2.New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 3.Indication: Adagloxad Simolenin (OBI-822) is a therapeutic cancer vaccine classified as an …

OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

1.Date of occurrence of the event:2024/01/03 2.New drug name or code: OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment that is based on TROP2 …

Announcement on behalf of Amaran that its institutional director changes its representative

1.Date of occurrence of the change:2023/12/29 2.Name of legal person: OBI Pharma Inc. 3.Name of the previous position holder: Chen-En Tsai 4.Resume of the previous position holder: Vice president of …

The Company’s Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board

1.Date of the board of directors resolution or date of occurrence of the change:2023/12/29 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the previous position holder: Yun Yen …